Efficacy of rituximab in refractory antisynthetase syndrome

$48.00 plus tax (Refund Policy)

Download / Buy Article:



We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B‐cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2011.02702.x

Affiliations: 1: Immunology Department 2: Respiratory Medicine Department, Royal Adelaide Hospital 3: Neuropathology Department, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

Publication date: March 1, 2012

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more